title: Efficacy of oseltamivir phosphate to horses inoculated with equine influenza A virus.
abstract: We investigated the efficacy of the oral administration of oseltamivir phosphate (OP) in horses experimentally infected with equine influenza A virus (H3N8). Nine horses were divided into three horses each of control, treatment and prophylaxis groups. An administration protocol for the treatment group (2 mg/kg of body weight, twice a day for five days) was started immediately after the onset of pyrexia (above 38.9 degrees C). An administration protocol for the prophylaxis group (2 mg/kg of body weight, once a day for five days) was started on a day before viral inoculation. In the treatment group, periods of virus excretion (mean days +/- standard deviation, 2.3 +/- 0.6) and pyrexia (2.0 +/- 0.0) were apparently shorter than those of the control group (6.0 +/- 0.0 and 8.0 +/- 1.0, respectively). In the prophylaxis group, although virus excretion and pyrexia were not prevented, the periods of virus excretion (5.0 +/- 0.0) and pyrexia (4.7 +/- 1.5) were shorter than those of the control group. Moreover, in the treatment and prophylaxis groups, bacterial counts of Streptococcus equi subsp. zooepidemicus known as the common pathogen of secondary bacterial pneumonia in bronchoalveolar lavage fluids collected seven days after inoculation were significantly fewer than that of the control group. The results indicated that the oral administration of OP to horses affected with equine influenza would contribute to reduce the magnitude of virus excretion, pyrexia and consequent secondary bacterial pneumonia.
authors.affiliation: Epizootic Research Center, Equine Research Institute, Japan Racing Association, Tochigi, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamanaka
authors.forename: Koji
authors.initials: K
authors.lastname: Tsujimura
authors.forename: Takashi
authors.initials: T
authors.lastname: Kondo
authors.forename: Seiji
authors.initials: S
authors.lastname: Hobo
authors.forename: Tomio
authors.initials: T
authors.lastname: Matsumura
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D005260:Female; D005334:Fever / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy* / Q000821:virology*; D006736:Horses; D053123:Influenza A Virus, H3N8 Subtype / Q000302:isolation & purification / Q000502:physiology*; D008168:Lung / Q000473:pathology / Q000821:virology; D008297:Male; D009976:Orthomyxoviridae Infections / Q000188:drug therapy / Q000662:veterinary* / Q000821:virology; D053139:Oseltamivir; D013997:Time Factors
chemical_list: D000081:Acetamides; D053139:Oseltamivir